Beijing Sungen Biomedical Technology Co., Ltd. (Sungen), which is an innovation-driven, clinical-stage biotechnology company incubated by Beijing Hotgen, is scheduled to attend and present in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, USA on Jan.13th-16th, 2025. The presentation will include latest updates over Sungen’s pipeline development targeting at cardiovascular and tumor diseases.
Interested parties are welcomed to contact Sungen or register at the relevant events. We are looking forward to meeting you in San Francisco. About SungenFounded in 2018, Beijing Sungen Biomedical Technology Co., Ltd. is dedicated to advancing human health through cutting-edge technologies. We are pioneering the development of First-in-Class (FIC) and Best-in-Class (BIC) antibody-based therapeutics. ContactsBusiness Development Contact: Runhui Lin Director of International Affairsrunhui.lin@sungenbiomed.com.cn Wei Zeng, PhDChief Representative, USAwei.zeng@sungenbiomed.com.cn
